Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
Early Phase 1
Recruiting
- Conditions
- Lupus NephritisIgG4-related Disease
- Interventions
- Biological: PRG-2311
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06497361
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy
Phase 4
Not yet recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- Procedure: transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapyDrug: PD-1,PD-L1
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06496815
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
Early Phase 1
Recruiting
- Conditions
- Lupus NephritisIgG4-related Disease
- Interventions
- Biological: PRG-1801
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06497387
- Locations
- 🇨🇳
Tongji Hospital, WuHan, Hubei, China
Clinical Trial to Evaluate the Effectiveness and Safety of a Remote Automated Ultrasound Diagnostic System for Automated Ultrasound Examinations: a Prospective, Multicenter Study
- Conditions
- UltrasoundLiverSpleenKidneyGallbladderPancreasThyroidCarotid Artery
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT06487312
- Locations
- 🇨🇳
Xin-Wu Cui, Wuhan, Hubei, China
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
Active, not recruiting
- Conditions
- Ovarian CancerBiomarker
- Interventions
- Genetic: Sequencing of DNA, RNA, and Proteins
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT06483425
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
Not Applicable
Not yet recruiting
- Conditions
- Idiopathic Inflammatory Demyelinating DiseaseMultiple SclerosisMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseNeuromyelitis Optica Spectrum DisorderAcute Disseminated Encephalomyelitis
- Interventions
- Drug: Calculus bovis sativus (CBS)
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06474520
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)
Not Applicable
Not yet recruiting
- Conditions
- Cerebral Small Vessel DiseasesIschemic Cerebrovascular DiseaseAcute Ischemic Stroke
- Interventions
- Drug: Calculus bovis sativus (CBS)
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 230
- Registration Number
- NCT06474507
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System
Recruiting
- Conditions
- Central Nervous System Diseases
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06467773
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease
Completed
- Conditions
- Refractory ThrombocytopeniaConnective Tissue Diseases
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06458803
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)
Recruiting
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 139
- Registration Number
- NCT06458972
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
© Copyright 2025. All Rights Reserved by MedPath